Propylene Glycol

Propylene Glycol

SCHEMBL55583

C[C@H](O)CO

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

SLC5A2

The experimentally established mechanism targets of Propylene Glycol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2149 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3823631-B1 METHODS OF TREATING HFPEF EMPLOYING DAPAGLIFLOZIN AND COMPOSITIONS COMPRISING THE SAME ASTRAZENECA AB (SE) 2026-05-20 EP claimed
EP-4739697-A1 PROCESS FOR THE PREPARATION OF DAPAGLIFLOZIN Zaklady Farmaceutyczne Polpharma S.A. (PL) 2026-05-13 EP claimed
US-12480061-B2 System and method for liquid fuel production from carbonaceous materials using recycled conditioned syngas THERMOCHEM RECOVERY INTERNATIONAL, INC. (US) 2025-11-25 US claimed
US-20250302782-A1 ADMINISTRATION OF BETA-HYDROXYBUTYRATE AND RELATED COMPOUNDS IN HUMANS FOR THE TREATMENT AND/OR PREVENTION OF RESPIRATORY ILLNESSES AXCESS GLOBAL SCIENCES, LLC 2025-10-02 US claimed
EP-4188389-B1 DAPAGLIFLOZIN FOR USE IN METHODS OF TREATING CHRONIC KIDNEY DISEASE ASTRAZENECA AB (SE) 2025-09-17 EP claimed
WO-2025125513-A1 SGLT2 INHIBITORS AND BAXDROSTAT FOR TREATING CHRONIC KIDNEY DISEASE AND HYPERTENSION AstraZeneca Ireland Limited (IE) 2025-06-19 WO claimed
US-20250108065-A1 METHODS OF TREATING PREDIABETES OR REDUCING THE RISK OF DEVELOPING TYPE 2 DIABETES WITH DAPAGLIFLOZIN ASTRAZENECA AB (SE) 2025-04-03 US claimed
CN-109892321-B Low-temperature preservation method for large-volume biological sample 中国科学技术大学 2025-03-28 CN claimed
CN-113897414-B Trace nucleic acid library construction method 湖南大地同年生物科技有限公司 2025-03-11 CN claimed
WO-2025008539-A1 PROCESS FOR THE PREPARATION OF DAPAGLIFLOZIN Zakłady Farmaceutyczne POLPHARMA S.A. (PL) 2025-01-09 WO claimed
US-6727088-B2 GENERATION OF (R)-1,-2-PROPANEDIOL; OBTAIN MICROORGANISM WHICH PREFERENTIALLY UTILIZES S-1,-2-PROPANEDIOL, PROPAGATE IN A SOLUTION CONTAINING RACEMIC MIXTURE OF 1,2 PROPANEDIOL, RECOVER R-1,-2-PROPANEDIOL DAISO CO., LTD. (JP) 2004-04-27 US claimed
WO-2003083126-A2 ENZYMATIC RESOLUTION OF PROPYLENE GLYCOL ALKYL (OR ARYL) ETHERS AND ETHER ACETATES DOW GLOBAL TECHNOLOGIES INC. (US) 2003-10-09 WO claimed
US-20020132314-A1 Process for preparation of (R)-1,-2-propanediol by microbes DAISO CO., LTD. (JP) 2002-09-19 US claimed
US-20020119909-A1 Preparation of enantiomerically enriched flavor and fragrance components RHODIA CHIREX, INC. 2002-08-29 US claimed
WO-2002057227-A2 PROCESS OF ENANTIOMERICALLY ENRICHED FLAVOR AND FRAGRANCE COMPONENTS RHODIA/CHIREX, INC. (US) 2002-07-25 WO claimed
WO-2002051395-A1 TREATMENT OF NEURODEGENERATIVE DISEASES CODON PHARMACEUTICALS, INC. (US) 2002-07-04 WO claimed
EP-1219715-A1 Process for preparation of (R)-1,2-propanediol by microbes DAISO CO., LTD. (JP) 2002-07-03 EP claimed
US-5990177-A CYCLIC AND ACYCLIC MONO-, DI- AND TRIALCOHOLS AS STIMULANTS TO TREAT DISEASES MEDIATED BY DEFICIENCIES IN THE NITRIC OXIDE/CYCLIC GUANOSINE MONOPHOSPHATE/PROTEIN KINASE G SIGNAL TRANSDUCTION PATHWAY; CARDIOVASCULAR; SKIN; NERVOUS SYSTEM CODON PHARMACEUTICALS, INC. (US) 1999-11-23 US claimed
US-4945187-A REDUCING LACTIDE KARL THOMAE GMBH (DE) 1990-07-31 US claimed
EP-0350852-A1 Process for the production of enantiomer-pure propane 1,2-diols BOEHRINGER INGELHEIM KG (DE) 1990-01-17 EP claimed